

3. (Amended) The agent for ameliorating low vasopressin level according to claim 1, wherein the substance is an anti-PTHrP antibody.

4. (Amended) The agent for ameliorating low vasopressin level according to claim 1, wherein the substance is at least one of a fragment of an anti-PTHrP antibody and a modified form of the fragment.

5. (Amended) The agent for ameliorating low vasopressin level according to claim 3 or 4, wherein the antibody is a humanized or chimeric antibody.

6. (Amended) The agent for ameliorating low vasopressin level according to claim 5, wherein the antibody is humanized #23-57-137-1 antibody.

7. (Amended) The agent for ameliorating low vasopressin level according to claim 3 or 4, wherein the antibody is a monoclonal antibody.

8. (Amended) The agent for ameliorating low vasopressin level according to any one of claims 1 to 4, wherein the low vasopressin level results from cancer.

9. (Amended) An agent for ameliorating at least one symptom caused by a decrease in vasopressin level comprising at least one substance that inhibits the binding between parathyroid hormone-related peptide (PTHrP) and a receptor thereof.

10. (Amended) The agent for ameliorating at least one symptom caused by a decrease in vasopressin level according to claim 9, wherein the decrease in vasopressin level results from cancer.

11. (Amended) The agent for ameliorating at least one symptom caused by a decrease in vasopressin level according to claim 9 or 10, wherein the symptom caused

1 cont
A
B1

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

by a decrease in vasopressin level is at least one symptom selected from the group consisting of polyuria, dehydration, mouth dryness and hyperosmolarity.

12. (Amended) An agent for ameliorating hyperosmolarity comprising at least one substance that inhibits the binding between parathyroid hormone-related peptide (PTHrP) and a receptor thereof.

13. (Amended) The agent for ameliorating hyperosmolarity according to claim 12, wherein the hyperosmolarity is associated with at least one of vomiting, diarrhea, fever, sweating, diabetes insipidus, or diabetes.

14. (Amended) An agent for ameliorating dehydration comprising at least one substance that inhibits the binding between parathyroid hormone-related peptide (PTHrP) and a receptor thereof.

15. (Amended) The agent for ameliorating dehydration according to claim 14, wherein the dehydration is associated with at least one of vomiting, diarrhea, fever, sweating, diabetes insipidus, or diabetes.

REMARKS

Applicants have amended claims 1-15 to conform with U.S. claim requirements. Specifically, Applicants have clarified the claims, eliminated improper multiple dependency, and provided proper antecedent basis support. No new matter has been added by these amendments and support for the changes made is in the original claims and the specification. These clarifying amendments do not change the scope of the

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com